Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

By Kathleen N. Moore, A. Angelergues, G. Konecny, Yolanda García, Susana Banerjee, Domenica Lorusso, Jung-Yun Lee, John W Moroney, N. Colombo, Andrzej Roszak and 20 more. 2023

Subfields: Obstetrics and Gynecology, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “FOLR1 positivity in 40% of our cases suggests a potential niche role in targeted therapies, such as folate receptor-alpha (FRα)- directed antibody-drug conjugates (e.g., mirvetux-imab soravtansine), which are under investigation in ovarian and endometrial cancers [31].”